Freida Blostein1, Elizabeth Levin-Sparenberg1, Julian Wagner2, Betsy Foxman3. 1. Center for Molecular and Clinical Epidemiology, University of Michigan, School of Public Health, Ann Arbor. 2. Independent, Lausanne, Switzerland. 3. Center for Molecular and Clinical Epidemiology, University of Michigan, School of Public Health, Ann Arbor. Electronic address: bfoxman@umich.edu.
Abstract
PURPOSE: Recurrent vulvovaginal candidiasis (RVVC), multiple episodes of vulvovaginal candidiasis (VVC; vaginal yeast infection) within a 12-month period, adversely affects quality of life, mental health, and sexual activity. Diagnosis is not straightforward, as VVC is defined by the combination of often nonspecific vaginal symptoms and the presence of yeast-which is a common vaginal commensal. Estimating the incidence and prevalence is challenging: most VVC is diagnosed and treated empirically, the availability for purchase of effective therapies over the counter enables self-diagnosis and treatment, and the duration of the relatively benign VVC symptoms is short, introducing errors into any estimates relying on medical records or patient recall. METHODS: We evaluate current estimates of VVC and RVVC and provide new prevalence estimates using data from a 2011 seven-country (n = 7345) internet panel survey on VVC conducted by Ipsos Health (https://www.ipsos.com/en). We also evaluate information on VVC-associated visits using the National Ambulatory Medical Care Survey. RESULTS: The estimated probability of VVC by age 50 varied widely by country (from 23% to 49%, mean 39%), as did the estimated probability of RVVC after VVC (from 14% to 28%, mean 23%). CONCLUSIONS: However estimated, the probability of RVVC was high suggesting RVVC is a common condition.
PURPOSE: Recurrent vulvovaginal candidiasis (RVVC), multiple episodes of vulvovaginal candidiasis (VVC; vaginal yeast infection) within a 12-month period, adversely affects quality of life, mental health, and sexual activity. Diagnosis is not straightforward, as VVC is defined by the combination of often nonspecific vaginal symptoms and the presence of yeast-which is a common vaginal commensal. Estimating the incidence and prevalence is challenging: most VVC is diagnosed and treated empirically, the availability for purchase of effective therapies over the counter enables self-diagnosis and treatment, and the duration of the relatively benign VVC symptoms is short, introducing errors into any estimates relying on medical records or patient recall. METHODS: We evaluate current estimates of VVC and RVVC and provide new prevalence estimates using data from a 2011 seven-country (n = 7345) internet panel survey on VVC conducted by Ipsos Health (https://www.ipsos.com/en). We also evaluate information on VVC-associated visits using the National Ambulatory Medical Care Survey. RESULTS: The estimated probability of VVC by age 50 varied widely by country (from 23% to 49%, mean 39%), as did the estimated probability of RVVC after VVC (from 14% to 28%, mean 23%). CONCLUSIONS: However estimated, the probability of RVVC was high suggesting RVVC is a common condition.
Authors: Sherine Mohamed Shawaky; Mariam Majed Ali Al Shammari; Manal Shafik Sewelliam; Abeer Abd El Rahim Ghazal; Ahmed Noby Amer Journal: AIMS Microbiol Date: 2022-05-05
Authors: Luciani Gaspar de Toledo; Matheus Aparecido Dos Santos Ramos; Patrícia Bento da Silva; Camila Fernanda Rodero; Veridiana de Sá Gomes; Anderson Noronha da Silva; Fernando Rogério Pavan; Isabel Cristiane da Silva; Fernando Bombarda Oda; Danilo Luis Flumignan; André Gonzaga Dos Santos; Marlus Chorilli; Margarete Teresa Gottardo de Almeida; Taís Maria Bauab Journal: Int J Nanomedicine Date: 2020-12-29
Authors: Newton Sergio de Carvalho; José Eleutério Junior; Ana Gabriela Travassos; Lutigardes Bastos Santana; Angélica Espinosa Miranda Journal: Rev Soc Bras Med Trop Date: 2021-05-17 Impact factor: 1.581
Authors: Jennifer M McCracken; Gisele A Calderon; Andrew J Robinson; Courtney N Sullivan; Elizabeth Cosgriff-Hernandez; Julie C E Hakim Journal: Reprod Sci Date: 2021-04-06 Impact factor: 2.924
Authors: Luca Spaggiari; Arianna Sala; Andrea Ardizzoni; Francesco De Seta; Dhirendra Kumar Singh; Attila Gacser; Elisabetta Blasi; Eva Pericolini Journal: Microbiol Spectr Date: 2022-05-02
Authors: Priya Uppuluri; Shakti Singh; Abdullah Alqarihi; Clint S Schmidt; John P Hennessey; Michael R Yeaman; Scott G Filler; John E Edwards; Ashraf S Ibrahim Journal: Front Immunol Date: 2018-06-15 Impact factor: 7.561